GlassScriptPhysician profile
Tram M Ho
NPI 1245464460
$12,362.91
in general payments reported to CMS, 2019-2025
26 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,505 · 2020: $4,302 · 2021: $169 · 2022: $427 · 2023: $601 · 2024: $1,218 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,704 · Entertainment: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,704.14 |
| Entertainment | $254.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,916.00 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $757.90 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Alcon Vision LLC | $646.72 | 2020-2025 | Dailies, Total30, Rocklatan |
| Abbvie INC. | $334.83 | 2022-2025 | |
| Shire North American Group INC | $291.94 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $260.48 | 2019-2021 | |
| Optos, INC. | $254.72 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $195.21 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $195.13 | 2024-2025 | Xdemvy |
| Coopervision INC. | $178.95 | 2019-2025 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $147.05 | 2019-2025 | |
| Biotissue Holdings INC. | $141.26 | 2024-2025 | |
| Lkc Technologies, INC. | $126.13 | 2024 | |
| Horizon Therapeutics Plc | $120.52 | 2022-2023 | Uplizna |
| Oyster Point Pharma, INC. | $113.32 | 2022-2024 | Tyrvaya, Ryzumvi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $108.81 | 2023-2025 | Vevye, Iheezo |
| Lombart Brothers, INC. | $103.78 | 2025 | Opd-III |
| Amgen INC. | $82.58 | 2024-2025 | Tepezza |
| Glaukos Corporation | $74.88 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $62.96 | 2024-2025 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $59.40 | 2020-2022 | |
| Rxsight INC | $51.80 | 2022-2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Novartis Pharmaceuticals Corporation | $50.17 | 2019 | |
| Sight Sciences, INC. | $39.44 | 2020-2021 | |
| Heidelberg Engineering, INC. | $29.39 | 2020 | |
| Thea Pharma INC. | $19.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tram Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.